Bacteria engineered to fight against cancer

Bacteriotherapy, combined with conventional methods, is effective in preventing tumor regression and metastasis. Immunotherapy, including the use of certain types of microorganisms, is expected to stimulate the immune system for selective eradication of cancer cells. Cancer engineered bacterial strain, known as SYNB1891, as a platform for biotherapeutic development, for the treatment of E. coli nissle. Bacterial strains can be responsible for the detection of carcinogens and the formation of short-chain fatty acids, affecting cell death and proliferation known as signal molecules in the immune system. In preventing carcinogenesis, probiotic bacteria can increase and decrease the production of anti-inflammatory cytokines, and which play an important role. Tumor-targeting bacteria have a multifaceted ability to suppress cancer, and bacteria accumulate and spread in tumors, and they can initiate antitumor resistance. Preventive stimulation, efficacy control, supply control, and protection of microbial therapy. Tiny strains such as Mycobacterium Bovis, Clostridium, Salmonella Typhimurium, and Listeria monocytosis have been studied with promising results. Creating new treatments through the control that will become an integral part of cancer care.